Nature Communications (Feb 2020)
Immune checkpoint modulation enhances HIV-1 antibody induction
- Todd Bradley,
- Masayuki Kuraoka,
- Chen-Hao Yeh,
- Ming Tian,
- Huan Chen,
- Derek W. Cain,
- Xuejun Chen,
- Cheng Cheng,
- Ali H. Ellebedy,
- Robert Parks,
- Maggie Barr,
- Laura L. Sutherland,
- Richard M. Scearce,
- Cindy M. Bowman,
- Hilary Bouton-Verville,
- Sampa Santra,
- Kevin Wiehe,
- Mark G. Lewis,
- Ane Ogbe,
- Persephone Borrow,
- David Montefiori,
- Mattia Bonsignori,
- M. Anthony Moody,
- Laurent Verkoczy,
- Kevin O. Saunders,
- Rafi Ahmed,
- John R. Mascola,
- Garnett Kelsoe,
- Frederick W. Alt,
- Barton F. Haynes
Affiliations
- Todd Bradley
- Duke Human Vaccine Institute, Duke University School of Medicine
- Masayuki Kuraoka
- Department of Immunology, Duke University School of Medicine
- Chen-Hao Yeh
- Department of Immunology, Duke University School of Medicine
- Ming Tian
- Program in Cellular and Molecular Medicine, Boston Children’s Hospital, Department of Genetic, Harvard Medical School, Howard Hughes Medical Institute
- Huan Chen
- Program in Cellular and Molecular Medicine, Boston Children’s Hospital, Department of Genetic, Harvard Medical School, Howard Hughes Medical Institute
- Derek W. Cain
- Duke Human Vaccine Institute, Duke University School of Medicine
- Xuejun Chen
- Vaccine Research Center, National Institute of Allergy and Infectious Diseases
- Cheng Cheng
- Vaccine Research Center, National Institute of Allergy and Infectious Diseases
- Ali H. Ellebedy
- Emory Vaccine Center, Emory University
- Robert Parks
- Duke Human Vaccine Institute, Duke University School of Medicine
- Maggie Barr
- Duke Human Vaccine Institute, Duke University School of Medicine
- Laura L. Sutherland
- Duke Human Vaccine Institute, Duke University School of Medicine
- Richard M. Scearce
- Duke Human Vaccine Institute, Duke University School of Medicine
- Cindy M. Bowman
- Duke Human Vaccine Institute, Duke University School of Medicine
- Hilary Bouton-Verville
- Duke Human Vaccine Institute, Duke University School of Medicine
- Sampa Santra
- Beth Israel Deaconess Medical Center, Harvard Medical School
- Kevin Wiehe
- Duke Human Vaccine Institute, Duke University School of Medicine
- Mark G. Lewis
- BIOQUAL, Inc
- Ane Ogbe
- Nuffield Department of Clinical Medicine, University of Oxford
- Persephone Borrow
- Nuffield Department of Clinical Medicine, University of Oxford
- David Montefiori
- Duke Human Vaccine Institute, Duke University School of Medicine
- Mattia Bonsignori
- Duke Human Vaccine Institute, Duke University School of Medicine
- M. Anthony Moody
- Duke Human Vaccine Institute, Duke University School of Medicine
- Laurent Verkoczy
- Duke Human Vaccine Institute, Duke University School of Medicine
- Kevin O. Saunders
- Duke Human Vaccine Institute, Duke University School of Medicine
- Rafi Ahmed
- Emory Vaccine Center, Emory University
- John R. Mascola
- Vaccine Research Center, National Institute of Allergy and Infectious Diseases
- Garnett Kelsoe
- Duke Human Vaccine Institute, Duke University School of Medicine
- Frederick W. Alt
- Program in Cellular and Molecular Medicine, Boston Children’s Hospital, Department of Genetic, Harvard Medical School, Howard Hughes Medical Institute
- Barton F. Haynes
- Duke Human Vaccine Institute, Duke University School of Medicine
- DOI
- https://doi.org/10.1038/s41467-020-14670-w
- Journal volume & issue
-
Vol. 11,
no. 1
pp. 1 – 16
Abstract
Elucidation of broadly neutralizing antibodies (bnAb) is a goal in HIV vaccine development. Here, Bradley et al. show that administration of CTLA-4 blocking antibody with vaccine antigens increases HIV-1 envelope antibody responses in macaques and a bnAb precursor mouse model.
